UNSPSC 51421503: Loteprednol

This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8CBU6KR16. European Medicines Agency schedules Loteprednol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08599MIG. Loteprednol generally arises in the molecular formula C21H27CLO5.

UNSPSC 51421503 Loteprednol is a Commodity code nominally identifying a specific ophthalmic corticosteroid, but the recent state and local opportunities posted under this code show a marked mismatch between the code's pharmaceutical product scope and the actual procurements being tracked. The two opportunities on record are Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, response due July 26, 2023) and the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription programs (posted April 3, 2026, response due April 3, 2026). Neither procurement involves loteprednol or ophthalmologic therapeutics; the code shows little relevant recent activity for its stated commodity.

The misclassification pattern suggests the code may be used as a catch-all for pharmaceutical procurement or pharmacy benefit management initiatives in some state and local systems, rather than specifically tracking loteprednol acquisition. The Seminole County opportunity targets emergency response and harm-reduction products—naloxone for opioid overdose reversal and drug deactivation systems—delivered quarterly to a county health facility, with standard compliance requirements including E-Verify and drug-free workplace certification. The Texas HHS RFI is exploratory, seeking vendor input on direct contracting models between state pharmacy programs and manufacturers outside traditional pharmacy benefit manager, GPO, and wholesaler channels. The two solicitations span different procurement stages (binding IFB versus preliminary market intelligence) and serve different program objectives. Given the code's narrow pharmaceutical focus and the absence of opportunities actually seeking loteprednol, business development professionals should verify code alignment when responding and monitor whether this classification pattern reflects intentional state/local taxonomy customization or procurement system artifacts.